RxDoctor Payments Data

Brian Riff, MD

Gastroenterology · Anaheim, CANPI 1194969030

Payments from drug & device makers

$78,809in general payments, 2019–2025

Across 566 payments — averaging $139.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$54K
  • AbbVie$9K
  • Braintree Laboratories, Inc.$4K
  • Olympus Medical Systems Corporation$3K
  • Ardelyx, Inc.$2K
  • Medtronic$1K
  • plus $6K from 32 others

What the payments were for

  • Consulting fees$3,8216%
  • Speaking & faculty fees$49,50072%
  • Travel & lodging$3,2245%
  • Food & beverage$11,75717%
  • Education$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,809 in reported general payments places this provider in the 85th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$659,956
Medicare patients
552
Services billed
32,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib21$140,963
LinzessLinaclotide116$71,818
XifaxanRifaximin16$58,175
VemlidyTenofovir Alafenamide31$43,892
CreonLipase/Protease/Amylase21$42,927
IbsrelaTenapanor Hcl11$18,009
MotegrityPrucalopride Succinate21$13,488
MounjaroTirzepatide12$12,607
TrulancePlecanatide22$12,175
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates192$11,802
Mesalamine46$9,506
MovantikNaloxegol Oxalate16$8,846
Dexlansoprazole DrDexlansoprazole27$5,037
Omeprazole285$3,268
Ursodiol31$2,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess, Creon$9,336$255,708158 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$941$70,35038 claims
GileadVemlidy$945$43,89231 claims
Ardelyx, Inc.Ibsrela$1,836$18,00911 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$359$13,48821 claims
Lilly USA, LLCMounjaro$155$12,60712 claims
Redhill Biopharma Inc.Movantik$34$8,84616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →